-
1
-
-
27444443876
-
American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute scientific statement
-
Grundy SM, Cleeman JI, Daniels SR, et al.: American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute scientific statement. Circulation 2005, 112:2735-2752.
-
(2005)
Circulation
, vol.112
, pp. 2735-2752
-
-
Grundy, S.M.1
Cleeman, J.I.2
Daniels, S.R.3
-
2
-
-
0344373794
-
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
-
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
-
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
-
(2002)
JAMA
, vol.288
, pp. 2981-2997
-
-
-
3
-
-
0347423198
-
-
Chobanian AV, Bakris GL, Black HR, et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
-
Chobanian AV, Bakris GL, Black HR, et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
-
-
-
-
4
-
-
34548463434
-
Diabetes and hypertension: Epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions
-
Schutta MH: Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J Cardiometab Syndr 2007, 2:124-130.
-
(2007)
J Cardiometab Syndr
, vol.2
, pp. 124-130
-
-
Schutta, M.H.1
-
5
-
-
33645225170
-
Glucose metabolism in patients with essential hypertension
-
Garcia-Puig J, Ruilope LM, Luque M, et al.: Glucose metabolism in patients with essential hypertension. Am J Med 2006, 119:318-326.
-
(2006)
Am J Med
, vol.119
, pp. 318-326
-
-
Garcia-Puig, J.1
Ruilope, L.M.2
Luque, M.3
-
7
-
-
34548391273
-
Skeletal muscle insulin resistance is fundamental to the cardiometabotic syndrome
-
Nistala, R, Stump CS: Skeletal muscle insulin resistance is fundamental to the cardiometabotic syndrome. J Cardiometab Syndr 2006, 1:47-52.
-
(2006)
J Cardiometab Syndr
, vol.1
, pp. 47-52
-
-
Nistala, R.1
Stump, C.S.2
-
8
-
-
0347993842
-
Obesity and hypertension
-
El-Atat F, Ashish A, Mcfarlane S, Sowers J: Obesity and hypertension. Endrinol Metab Clin N Am 2003, 32:823-854.
-
(2003)
Endrinol Metab Clin N Am
, vol.32
, pp. 823-854
-
-
El-Atat, F.1
Ashish, A.2
Mcfarlane, S.3
Sowers, J.4
-
9
-
-
38549134399
-
Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes
-
Takata Y, Osawa H, Krata M, et al.: Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008, 51:534-539.
-
(2008)
Hypertension
, vol.51
, pp. 534-539
-
-
Takata, Y.1
Osawa, H.2
Krata, M.3
-
10
-
-
33748305533
-
The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD?
-
Diamant M, Tushuizen M: The metabolic syndrome and endothelial dysfunction: common highway to type 2 diabetes and CVD? Curr Diab Rep 2006, 6:279-286.
-
(2006)
Curr Diab Rep
, vol.6
, pp. 279-286
-
-
Diamant, M.1
Tushuizen, M.2
-
11
-
-
21744452983
-
PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin
-
Clasen R, Schupp M, Foryst-Ludwig A, et al.: PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005, 46:137-143.
-
(2005)
Hypertension
, vol.46
, pp. 137-143
-
-
Clasen, R.1
Schupp, M.2
Foryst-Ludwig, A.3
-
12
-
-
34249003028
-
The role of c-reactive protein in the metabolic syndrome and diabetes mellitus
-
Sowers JR: The role of c-reactive protein in the metabolic syndrome and diabetes mellitus. Endocrinologist 2007, 17:163-168.
-
(2007)
Endocrinologist
, vol.17
, pp. 163-168
-
-
Sowers, J.R.1
-
13
-
-
35148840913
-
Reninangiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance
-
Cooper SA, Whaley-Connell A, Habibi J, et al.: Reninangiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007, 293:H2209-H2223.
-
(2007)
Am J Physiol Heart Circ Physiol
, vol.293
-
-
Cooper, S.A.1
Whaley-Connell, A.2
Habibi, J.3
-
15
-
-
20044376702
-
The pathobiology of diabetic complications: A unifying mechanism
-
Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
-
(2005)
Diabetes
, vol.54
, pp. 1615-1625
-
-
Brownlee, M.1
-
16
-
-
34547443383
-
Adiponectin and insulin sensitivity in primary aldosteronism
-
Fallo F, Della Mea P, Sonino N, et al.: Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 2007, 20:855-861.
-
(2007)
Am J Hypertens
, vol.20
, pp. 855-861
-
-
Fallo, F.1
Della Mea, P.2
Sonino, N.3
-
17
-
-
36148934920
-
The effect of leisure-time physical activity on the presence of metabolic syndrome in patients with manifest arterial disease. The SMART study
-
Brouwer BG, Visseren FLJ, van der Graff Y: The effect of leisure-time physical activity on the presence of metabolic syndrome in patients with manifest arterial disease. The SMART study. Am Heart J 2007, 154:1146-1152.
-
(2007)
Am Heart J
, vol.154
, pp. 1146-1152
-
-
Brouwer, B.G.1
Visseren, F.L.J.2
van der Graff, Y.3
-
18
-
-
26444457387
-
Effect of exercise training on plasma levels of c-reactive protein in healthy adults: The heritage family study
-
Lakka TA, Lakka HM, Rankinen T, et al.: Effect of exercise training on plasma levels of c-reactive protein in healthy adults: the heritage family study. Eur Heart J 2005, 26:2018-2025.
-
(2005)
Eur Heart J
, vol.26
, pp. 2018-2025
-
-
Lakka, T.A.1
Lakka, H.M.2
Rankinen, T.3
-
19
-
-
0842333082
-
Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort
-
McKeown N, Meigs JB, Liu S, et al.: Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004, 27:538-546.
-
(2004)
Diabetes Care
, vol.27
, pp. 538-546
-
-
McKeown, N.1
Meigs, J.B.2
Liu, S.3
-
20
-
-
39549111696
-
Dietary intake and the development of the metabolic syndrome. The Atherosclerosis Risk in Communities Study (ARIC)
-
Lutsey PL, Steffen LM, Stevens J.: Dietary intake and the development of the metabolic syndrome. The Atherosclerosis Risk in Communities Study (ARIC). Circulation 2008, 117:754-761.
-
(2008)
Circulation
, vol.117
, pp. 754-761
-
-
Lutsey, P.L.1
Steffen, L.M.2
Stevens, J.3
-
21
-
-
2342652390
-
Adverse prognostic significance of new diabetes in treated hypertensive subjects
-
Verdecchia P, Reboldi G, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:1-7.
-
(2004)
Hypertension
, vol.43
, pp. 1-7
-
-
Verdecchia, P.1
Reboldi, G.2
Angeli, F.3
-
22
-
-
33746367481
-
Antihypertensive medications and the risk of incident type 2 diabetes
-
Taylor EN, Hu FB, Curhan GC: Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006, 29:1065-1070.
-
(2006)
Diabetes Care
, vol.29
, pp. 1065-1070
-
-
Taylor, E.N.1
Hu, F.B.2
Curhan, G.C.3
-
23
-
-
34548428300
-
Treatment of hypertension with thiazides: Benefit or damage-effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance
-
Shargorodsky M, Boaz M, Davidovitz I, et al.: Treatment of hypertension with thiazides: benefit or damage-effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance. J Cardiometab Syndr 2007, 2:16-23.
-
(2007)
J Cardiometab Syndr
, vol.2
, pp. 16-23
-
-
Shargorodsky, M.1
Boaz, M.2
Davidovitz, I.3
-
24
-
-
33749061108
-
Metabolic safety of antihypertensive drugs: Myth vs. reality
-
Stas S, Appesh L, Sowers JR: Metabolic safety of antihypertensive drugs: myth vs. reality. Curr Hypertens Rep 2006, 8:403-408.
-
(2006)
Curr Hypertens Rep
, vol.8
, pp. 403-408
-
-
Stas, S.1
Appesh, L.2
Sowers, J.R.3
-
25
-
-
33644842033
-
Development of diabetes with thiazide diuretics: The potassium issue
-
Carter BL, Basile J: Development of diabetes with thiazide diuretics: the potassium issue. J Clin Hypertens 2005, 7:638-640.
-
(2005)
J Clin Hypertens
, vol.7
, pp. 638-640
-
-
Carter, B.L.1
Basile, J.2
-
26
-
-
56349172623
-
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: VALUE randomised trial
-
Stevo J, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: VALUE randomised trial. Lancet 2004, 28:221-226.
-
(2004)
Lancet
, vol.28
, pp. 221-226
-
-
Stevo, J.1
Kjeldsen, S.E.2
Weber, M.3
-
27
-
-
38749150577
-
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
-
Wright JT, Harris-Haywood S, Pressel S, et al.: Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008, 168:207-217.
-
(2008)
Arch Intern Med
, vol.168
, pp. 207-217
-
-
Wright, J.T.1
Harris-Haywood, S.2
Pressel, S.3
-
28
-
-
9144236380
-
Recommendations for special populations: The treatment of hypertension in diabetes mellitus
-
Tan AS, Kuppuswamy S, Whaley-Connell AT, et al.: Recommendations for special populations: the treatment of hypertension in diabetes mellitus. Endocrinologist 2004, 14:368-381.
-
(2004)
Endocrinologist
, vol.14
, pp. 368-381
-
-
Tan, A.S.1
Kuppuswamy, S.2
Whaley-Connell, A.T.3
-
29
-
-
34250638587
-
Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus
-
Bank AJ, Kelly AS, Thelen AM, et al.: Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hyperten 2007, 20:777-783.
-
(2007)
Am J Hyperten
, vol.20
, pp. 777-783
-
-
Bank, A.J.1
Kelly, A.S.2
Thelen, A.M.3
-
30
-
-
7744237066
-
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial
-
Bakris GL, Fonseca V, Katholi RE, et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004, 292:2227-2236.
-
(2004)
JAMA
, vol.292
, pp. 2227-2236
-
-
Bakris, G.L.1
Fonseca, V.2
Katholi, R.E.3
-
31
-
-
32944461232
-
Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients
-
Celik T, Iyisoy A, Kursaklioglu H, et al.: Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertension 2006, 24:591-596.
-
(2006)
J Hypertension
, vol.24
, pp. 591-596
-
-
Celik, T.1
Iyisoy, A.2
Kursaklioglu, H.3
-
32
-
-
33845366982
-
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide
-
Villamil A, Chrysant SG, Calhoun D, et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007, 25:217-226.
-
(2007)
J Hypertens
, vol.25
, pp. 217-226
-
-
Villamil, A.1
Chrysant, S.G.2
Calhoun, D.3
-
33
-
-
40049111351
-
Antihypertensive therapy with aliskiren
-
Luft FC, Weinberger MH: Antihypertensive therapy with aliskiren. Kidney Int 2008, 73:679-683.
-
(2008)
Kidney Int
, vol.73
, pp. 679-683
-
-
Luft, F.C.1
Weinberger, M.H.2
-
34
-
-
24144490705
-
The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes
-
Gillespie EL, White CM, Kardas M, et al.: The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005, 28:2261-2266.
-
(2005)
Diabetes Care
, vol.28
, pp. 2261-2266
-
-
Gillespie, E.L.1
White, C.M.2
Kardas, M.3
-
35
-
-
33749590988
-
DREAM Trial Investigators: Effect of ramipril on the incidence of diabetes
-
Bosch J, Yusuf S, Gerstein HC, et al.; DREAM Trial Investigators: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551-1562.
-
(2006)
N Engl J Med
, vol.355
, pp. 1551-1562
-
-
Bosch, J.1
Yusuf, S.2
Gerstein, H.C.3
-
36
-
-
34548420712
-
-
Patel A, ADVANCE Collaborative Group, MacMahon S, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840.
-
Patel A, ADVANCE Collaborative Group, MacMahon S, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840.
-
-
-
-
37
-
-
0037160969
-
LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol
-
Lindholm LH, Ibsen H, Dahlof B, et al.; LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:1004-1010.
-
(2002)
Lancet
, vol.359
, pp. 1004-1010
-
-
Lindholm, L.H.1
Ibsen, H.2
Dahlof, B.3
-
38
-
-
0042154108
-
Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)
-
Lindholm LH, Persson M, Alaupovic P, et al.: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertension 2003, 21:1563-1574.
-
(2003)
J Hypertension
, vol.21
, pp. 1563-1574
-
-
Lindholm, L.H.1
Persson, M.2
Alaupovic, P.3
-
39
-
-
34548731369
-
Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome
-
Ichikawa Y: Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007, 46:1331-136.
-
(2007)
Intern Med
, vol.46
, pp. 1331-2136
-
-
Ichikawa, Y.1
-
40
-
-
0033517302
-
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
-
Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
-
(1999)
N Engl J Med
, vol.341
, pp. 709-717
-
-
Pitt, B.1
Zannad, F.2
Remme, W.J.3
-
41
-
-
0037417252
-
Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
-
Pitt B, Remme W, Zannad F, et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
-
(2003)
N Engl J Med
, vol.348
, pp. 1309-1321
-
-
Pitt, B.1
Remme, W.2
Zannad, F.3
-
42
-
-
34547136451
-
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling
-
Stas S, Whaley-Connell A, Habibi J, et al.: Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007, 148:3773-3780.
-
(2007)
Endocrinology
, vol.148
, pp. 3773-3780
-
-
Stas, S.1
Whaley-Connell, A.2
Habibi, J.3
-
43
-
-
20544453256
-
Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage
-
Fiebeler A, Nussberger J, Shagdarsuren E, et al.: Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111:3087-3094.
-
(2005)
Circulation
, vol.111
, pp. 3087-3094
-
-
Fiebeler, A.1
Nussberger, J.2
Shagdarsuren, E.3
|